RavenConnects
Novotech logo

Novotech is the leading Asia-Pacific biotech CRO. Novotech is a clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biopharmaceutical clients conducting clinical trials in Asia, the US and globally. Novotech has over 2500 staff working across our offices in 13 geographies.

Contact Vendor
Novotech
Pharma Intelligence UK Ltd

Combating a wide range of diseases with RNA Therapies

In this latest white paper, global leading CRO, Novotech, explores the latest advancements, trends and challenges in global RNA research. Access it now to gain insights and key statistics on:
Whitepaper Clinical Studies Pharmaceutical Research and Development
Novotech
Pharma Intelligence UK Ltd

Advances and opportunities in Liver Cancer research

Liver cancer is one of the leading causes of cancer death, with new cases predicted to rise by an alarming 70% by the time we reach 2025 (vs. 2022). Hepatocellular carcinoma, or HCC, accounts for 90% of cases, and poses significant challenges in treatment. Access this in-depth report to explore the global drug development landscape, and how promising advances in treatments are providing hope for the future. Explore topics including:
Report Clinical Studies Pharmaceutical Research and Development
Novotech
Pharma Intelligence UK Ltd

Radiopharmaceuticals: Global Clinical Trial Landscape (2024)

Established originally from radiation therapy, radiopharmaceuticals have made significant development progress in recent years. In 2018, the FDA approved Lutathera for neuroendocrine tumors, signifying a new hope in the treatment of solid tumors. As the global clinical trial landscape continues to evolve, this white paper explores:
Whitepaper Clinical Studies Pharmaceutical Research and Development
Novotech
Pharma Intelligence UK Ltd

New EU Clinical Trial Regulations

Explore the challenges and benefits for biotechs conducting trials in the EU, and why partnerships are crucial to support the trial journey, as they discuss:
Report Clinical Studies Pharmaceutical Research and Development
Novotech
Pharma Intelligence UK Ltd

Antibody-Drug Conjugates: Global Clinical Trial Landscape (2024)

Don’t miss critical data and informative market analysis that examines ADC’s current state, development trends, and future potential. This data-rich report features:
Report Clinical Studies Pharmaceutical Research and Development
Novotech
Pharma Intelligence UK Ltd

Oesophageal Cancer: Global Clinical Trial Landscape (2024)

Discover more about this disease and the critical clinical research being conducted to combat and treat it, in this data-packed report. Download the report now to explore:
Report Clinical Studies Pharmaceutical Research and Development
Novotech
Pharma Intelligence UK Ltd

Overcoming barriers in R&D

Industry experts at the BIO International Convention held in San Diego, California, discussed the key strategies for success in clinical trials. Discover insights on enhancing operational efficiency and effective communication, setting clear investor expectations, harnessing artificial intelligence and machine learning capabilities, and the impact of CRO partnerships.
Report Clinical Studies Pharmaceutical Research and Development
Novotech
Pharma Intelligence UK Ltd

Navigating the biotech landscape: Insights Into Clinical Trials, Funding Trends, Challenges, And Transformations Amidst Covid-19 And Beyond (2023)

The pharmaceutical and biotech industry shows a robust commitment to innovation, despite setbacks, such as the ongoing pandemic, economic pressures, increased competition and unsuccessful clinical trials. Gain key insights from varying stakeholders on their individual challenges, and why they feel the optimistic about the future, as they explore:
Report Clinical Studies Pharmaceutical Research and Development
Novotech
Pharma Intelligence UK Ltd

Epilepsy - Global Clinical Trial Landscape (2024)

Around one third of individuals with the disease are drug-resistant, highlighting a significant need for innovative therapies to address this and the disease as a whole. Biomarkers and precision therapies show encouraging results, but there is still work to be done. In this latest report by Novotech, gain comprehensive insight on:
Report Clinical Studies Pharmaceutical Research and Development